WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
- 31 December 1996
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32, S17-S20
- https://doi.org/10.1016/s0959-8049(96)00313-9
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Antimutagenic Effects of Radioprotector WR-2721 Against Fission-spectrum Neutrons and60Co γ-rays in MiceInternational Journal of Radiation Biology, 1992
- Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721Cancer, 1988
- The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721)American Journal of Clinical Oncology, 1982
- Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamideBritish Journal of Cancer, 1980